First mover in making RNA sequencing clinically actionable in oncology

Transcription

1 First mover in making sequencing clinically actionable in oncology

2 Saving lives and making healthcare delivery more effective: by selecting the best drug for the patient, and the best patient for the drug by sequencing

3 Only 1 out of 4 cancer treatments prolong life!

4 $80 billion is spent on cancer drugs while 8 million patients die

5 DIAGNOSED AUGUST 2001 DIAGNOSED OCTOBER

6 Gitte Pedersen, M.Sc. Morten Pedersen, Ph.D. CEO & Co-founder Big Biotech +$1B deals MSc Chemical Engineering Skier & surfer CTO & CO-Founder Inventor PhD in Genetics Paraglider

7 How can we cure cancer?

8 We can cure cancer by genetically matching the patients to a drug that actually works: Immune Therapy Jesper Zeuthen, D.Sc. CMO The Danish Cancer Society Co-founder of GenMab & Dandrit Leader in immune therapy Raised > $650MM for Bankinvest Trekker

9 Immune therapy is as close as we get to a cure

10 $1million

11 Morten Middelfart Ph.D. CIO 2 Ph.D. s Big Data 25 worldwide patents +20 years of analyzing Big Data Skydiver Tanya Kanigan, Ph.D. COO Postdoc MIT Cofounded BioTrove Co-Inventor of OpenArray Weekend farmer

12 -seq July saved 7th, 2012 Dr. Wartman s life July 7th, 2012

13 One from Sample to Answer in 1 week 1/10 of the cost and 1000 x less data Isolate Prepare One libraries Sequence and analyze data Match profile to actionable genes Generate One report

14 Our biggest moment Triple-negative breast cancer ONLY chemo available very POOR prognosis 2000 clinical trials? One identified 6 approved drugs 1drug approved in breast 5drug approved in other 30 clinical trials

15 Competition: DNA panels won t work for immune therapy 2 immune therapies Effective in 20% of the patients 15

16 $50B 14M newly diagnosed/year $20B 5.6 mill developed world $1B 4% in clinical trials

17 Most scalable platform in the market Cancer Auto immune CNS Infectious

18 Gitte Pedersen,

19 Credentials #2 in the Women s Founders Pitch event in LA Top 10 in Richard Bransons XTC, Necker Island Top 10 Molecular Tri-Conference, San Francisco In the top 250 Red Herring - going for top 100

20 Finding the right drug for the patient and the right patient for the drug by sequencing First mover in making sequencing clinically actionable in oncology Saving lives and making healthcare delivery more effective by assisting doctors select the best drug for their patient, and Pharma companies select the best patient for their drug Quick Facts: Founded: 2009 Employees: 10 Company Stage: Commercial launch Patents: Issued US (6,958,217), and European patents and several new patents pending Use of Proceeds: Launch of One and CLIA certification. Advisors: Legal Duane Morris LLP, Accounting, Malc & Company Investors: Centurion Holding LLC, Investor Circle, Biogen founder, Seattle Women s Impact Fund, Pipeline Angels Scientific Advisors: Winston Kuo, Ph.D. Director Harvard Catalyst, Ulrik Nielsen, Ph.D. Founder & CTO Merrimack; Niels Tommerup, Ph.D. Head of Centre for Functional Genome Research; Karen Brøndum- Nielsen, Ph.D., Head of Medical Genetics, John F. Kennedy Institute; Per Guldberg, Ph.D. Professor and Head of the Genomics Lab at the Danish Cancer Society Executive Summary: Our mission is to save lives and to make health care delivery more efficient. The inconvenient truth in oncology is that only 1 out of 4 cancer treatments prolong life. We are providing an actionable report to the doctor using our One platform that can guide the doctor to the most efficient treatment for the individual patient. All our competitors are sequencing DNA, however DNA fails to predict response to the new immune therapies. Market: The market for genomic tools and diagnostic is $6 billion, growing more than 20% per year. Analysis is the single largest application across platforms (Q-PCR, Arrays, Sequencing) and a well established marker species for disease diagnostic algorithms of reimbursed diagnostics in large markets such as cancer, organ transplant and cardiology. Business Model: We are currently selling the One platform as a tool to help pharma and key academic institutions select the right patients into clinical trails. It is the plan to launch One as a service for all patients which will require a CLIA certification. Partners and collaborators: We have signed up 17 beta testers among large pharma and diagnostic companies and key academic institutions and moved the first two to paying customers. Existing partnerships: Genomic Expression is working with IBM in building out our HIPAA compliment cloud platform. Our principle is to ensure safety of our partners as well as patients data. We can develop API to customers systems to leverage the power of combining genetic data with clinical data. Technology: We have re-engineered -seq for clinical applications in oncology and combined that with our own proprietary bioinformatics and a database with all actionable genes in oncology. This enables us to get from samples to answer in less than a week. We have pending as well as issued patents on our technology.

21 Business Advisors: Paul Billing, former CMO Life Tech, now JnJ, Geert Cauwenbergh, CEO at RXi Pharmaceuticals Cor, Torben Skarsfeldt, D.Sc. former Director, at Lundbeck A/S, Mette Skjold Rotboll, Founder and Non Executive Director of Vigil Wealth Management, Mostafa Analoui, Ph.D.- Head of Healthcare at The Livingston Group Competitors Competition has focused on DNA sequencing, where Foundation Medicine is a clear first mover, however DNA sequencing can not predict response to the new immune therapies in oncology. Furthermore they are using panels, that are being outdated due to the rapid innovation cycles, and requires re-validation to make changes due to regulatory. Exit Strategy: GEx will be an attractive acquisition target for a large established Genomics Tool and/or diagnostic company. Trade sales in the sequencing space have been between $30 million and $750 million for pre-revenue companies. The company may also go public depending on the market situation. One Platform: Genomic Expression was the diagnostic partner in Denmark s first large sequence based project called Genome Denmark. The project was funded by the Danish Hightech Fund with $32 million.the One technology and vision was created as a result of this public private partnership. Access to historic samples in a single payer system enables Genomic Expression to develop disease prognostic algorithms in any disease. One is portable outside oncology with an update to the cloud Because One is not using baits or panels, but uniquely identify and quantify 20,000 s in ONE assay, it can keep pace with the rate of new discovery by updating the cloud. Furthermore it is also portable outside oncology with an update to the actionable database. That makes One the most scalable platform in the market. Contact: Gitte Pedersen, CEO: glp@genomicexpression.com 375 Park Avenue, Suite 2607 New York, NY Phone USA: +1 (646) Mobile: Management team with proven track record and start-up DNA Gitte Pedersen, CEO is a former executive from NovoZymes. She successfully developed and launched multiple products into multiple industries world wide. She left to advise the Danish Government, and a number of Biotech companies, where she structured several deals with an aggregate of +$1Billion with big pharma such at Merck, Takeda, GSK, Wyeth and others. Morten Pedersen, CTO, PhD is the inventor of the technologies with a very strong innovation track record from Chr Hansen. Jesper Zeuthen, CMO, is the co-founder of GeneMap and DanDrit, IPO's, and established the Danish Cancer Society. Morten Middelfart 2 PhDs in big data and strong entrepreneurial track record. Tanya Kanigan, COO, post-doc from MIT, developed OpenArray(R), spun it out into BioTrove which was later sold to Life Technology. Geoffrey Folkerth, CFO was the former CFO of Pathway Genomics, where he raised $20 mill.